1. Evolution of renal function in African patients initiating second line antiretroviral treatment : Findings from the 2LADY-ANRS 12169 trial

Cournil A, Hema A, Eymard-Duvernay S, Ciaffi L, Badiou S, Kabore F, Diouf A, Manga N, Le mo,g V, Reynes J, Koulla Shiro S, Delaporte E, the 2LADY Study Group

Antiviral Therapy, 2016 [cited 2016 Oct 6]. doi: 10.3851/IMP3097

2. Getting pregnant in HIV clinical trials: women’s choice and safety needs. The experience from the ANRS12169-2LADY and ANRS12286-MOBIDIP trials, HIV Clinical Trials, DOI: 10.1080/15284336.2016.1248624

Serris A1, Zoungrana J2, Diallo M3, Toby R4, Mpoudi Ngolle M5, Le Gac S6, Coutherut J7, Cournil A1, De Beaudrap P7, Koulla-Shiro S4,8, Delaporte E1,9, Ciaffi L1.

HIV Clinical Trials, DOI: 10.1080/15284336.2016.1248624, Pages 1-9 | Published online: 01 Nov 2016

3. High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.

Guichet E, Aghokeng A, Serrano L, Bado G, Toure-Kane C, Eymard-Duvernay S, et al.

AIDS Res Hum Retroviruses. 2016 Aug 2;

4. Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon.

Guichet E, Aghokeng A, Eymard-Duvernay S, Vidal N, Ayouba A, Mpoudi Ngole E, et al.

J Virol Methods. 2016 Sep 5;237:121–6

5. Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaoundé, Cameroon.

Galy A, Ciaffi L, Le Moing V, Eymard-Duvernay S, Abessolo H, Toby R, et al.

Antivir Ther (Lond). 2016 Feb 16;

6. HandiVIH. A population-based survey to understand the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations.

De Beaudrap P, Pasquier E, Noelle A, et al.

BMJ Open. 2016; 6(2):e008934

7. HandiVIH. Understanding the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations

De Beaudrap P, Pasquier E, Noelle  A, et al.

Open BMJ 2016, 6(2):e008934

8. Higher prevalence of HIV infection among people with disabilities: results of a population-based observational study in Yaoundé, Cameroon (HandiVIH)

De Beaudrap P, Beninguisse G,  Pasquier E, Tchoumkeu A, Touko A, Frida Essomba3, Brus A,  Aderemi T, Hanass-Hancock J, Henning Eide A, Mac-Seing M, Mont D.

En cours de révision

9. Field evaluation of an open and polyvalent universal HIV-1/SIVcpz/SIVgor quantitative RT-PCR assay for HIV-1 viral load monitoring in comparison to Abbott RealTime HIV-1 in Cameroon.

Guichet E1, Aghokeng A2, Eymard-Duvernay S1, Vidal N1, Ayouba A1, Mpoudi Ngole E3, Delaporte E1, Ciaffi L1, Peeters M4.

J Virol Methods. 2016; 237:121-126.

10. High Viral Load and Multidrug Resistance Due to Late Switch to Second-Line Regimens Could Be a Major Obstacle to Reach the 90-90-90 UNAIDS Objectives in Sub-Saharan Africa.

Guichet E1, Aghokeng A1,2, Serrano L1, Bado G3, Toure-Kane C4, Eymard-Duvernay S1, Villabona-Arenas CJ1,5, Delaporte E1, Ciaffi L1, Peeters M1.

AIDS Res Hum Retroviruses. 2016 Aug 2. [Epub ahead of print]

11. Performance of Xpert MTB/RIF and Alternative Specimen Collection Methods for the Diagnosis of Tuberculosis in HIV-Infected Children.

Marcy O, Ung V, Goyet S, Borand L, Msellati P, Tejiokem M, Nguyen Thi NL, Nacro B, Cheng S, Eyangoh S, Pham TH, Ouedraogo AS, Tarantola A, Godreuil S, Blanche S, Delacourt C; PAANTHER study group.

Clin Infect Dis. 2016 May 1;62(9):1161-8. doi: 10.1093/cid/ciw036. Epub 2016 Feb 7.

 

12. Cryptococcus neoformans isolates from Yaoundé HIV infected patients exhibited intra individual genetic diversit0y and variation in antifungal susceptibility profiles between isolates from the same patient.
Kammalac Ngouana T, Drakulovski P, Krasteva D, Kouanfack C, Reynes J, Delaporte E, Boyom FF, Mallié M, Bertout S.J Med Microbiol. 2016 Apr 20. doi: 10.1099/jmm.0.000265. [Epub ahead of print ]
13. Primate immunodeficiency virus classification and nomenclature: Review.

Foley BT, Leitner T, Paraskevis D, Peeters M.

Infect Genet Evol. 2016; 46:150-158.

14. The potency of Nef-mediated SERINC5 antagonism correlates with the prevalence of primate lentiviruses in the wild.

Heigele A, Kmiec D, Regensburger K, Langer S, Peiffer L, Stürzel CM, Sauter D, Peeters M, Pizzato M, Learn GH, Hahn BH, Kirchhoff F.

Cell Host Microbe. 2016;20(3):381-91.

15. Cospeciation of gut microbiota with hominids.

Moeller AH, Caro-Quintero A, Mjungu D, Georgiev AV, Lonsdorf EV, Muller MN, Pusey AE, Peeters M, Hahn BH, Ochman H.

Science. 2016;353(6297):380-2.

16. Multigenomic Delineation of Plasmodium Species of the Laverania Subgenus Infecting Wild-Living Chimpanzees and Gorillas.

Liu W, Sundararaman SA, Loy DE, Learn GH, Li Y, Plenderleith LJ, Ndjango JB, Speede S, Atencia R, Cox D, Shaw GM, Ayouba A, Peeters M, Rayner JC, Hahn BH, Sharp PM.

Genome Biol Evol. 2016 Jul 2;8(6):1929-39. doi: 10.1093/gbe/evw128.

17. Genomes of cryptic chimpanzee Plasmodium species reveal key evolutionary events leading to human malaria.

Sundararaman SA, Plenderleith LJ, Liu W, Loy DE, Learn GH, Li Y, Shaw KS, Ayouba A, Peeters M, Speede S, Shaw GM, Bushman FD, Brisson D, Rayner JC, Sharp PM, Hahn BH.

Nat Commun. 2016 Mar 22; 7:11078. doi: 10.1038/ncomms11078.

18. Predictors of depression among patients on art in a rural health district in North West Cameroon.
Asangbeh SL, Sobngwi JL, Ekali GL, Eyoum C, Msellati P.AIDS Care. 2016 Feb;28(2):205-8. doi: 10.1080/09540121.2015.1074654.
19. Incidence of infectious morbidity events after second-line antiretroviral therapy initiation in HIV-infected adults in Yaoundé, Cameroon.

Galy A1, Ciaffi L, Le Moing V, Eymard-Duvernay S, Abessolo H, Toby R, Ayangma L, Le Gac S, Mpoudi-Etame M, Koulla-Shiro S, Delaporte E, Cournil A; the, Group LS.

Antivir Ther. 2016 Feb 16. doi: 10.3851/IMP3030. [Epub ahead of print]

20. First evidence of transmission of an HIV-1 M/O intergroup recombinant virus.

Ngoupo PA, Sadeuh-Mba SA, De Oliveira F, Ngono V, Ngono L, Tchendjou P, Penlap V, Mourez T, Njouom R, Kfutwah A, Plantier JC.

AIDS. 2016 Jan 2;30(1):1-8.

21. How do supply-side factors influence informal payments for healthcare? The case of HIV patients in Cameroon .

KANKEU HT, BOYER S, FODJO TOUKAM R, ABU-ZAINEH M.

Int J Health Plann Mgmt 2016; 31: E41–E57. DOI: 10.1002/hpm.2266.

22. Estimating mother-to-child HIV transmission rates in Cameroon in 2011: a computer simulation approach.

Nguefack HL1Gwet H2Desmonde S3,4Oukem-Boyer OO5,6Nkenfou C7Téjiokem M8Tchendjou P9Domkam I10Leroy V11,12,13Alioum A14,15;Inserm U897 Modeling Infectious Diseases in Low-Income Countries Study Group.

BMC Infect Dis. 2016 Jan 12;16:11. doi: 10.1186/s12879-016-1336-2.

23. Impediments to HIV testing in HIV-infected children and teenagers in Africa: look for them where they are!
Msellati P, Ateba Ndongo F, Hejoaka F, Nacro B.Med Sante Trop. 2016 Jan-Mar;26(1):10-4. doi: 10.1684/mst.2015.0519.
24. HIV-1 group O infection in Cameroon from 2006 to 2013: Prevalence, genetic diversity, evolution and public health challenges.

Villabona-Arenas CJ, Domyeum J, Mouacha F, Butel C, Delaporte E, Peeters M, Mpoudi-Ngole E, Aghokeng AF.

Infect Genet Evol. 2015 Dec;36:210-6. doi: 10.1016/j.meegid.2015.09.006. Epub 2015 Sep 11.

25. Molecular characterization of a new mosaic Simian Immunodeficiency Virus in a naturally infected tantalus monkey (Chlorocebus tantalus) from Cameroon: a challenge to the virus-host co-evolution of SIVagm in African green monkeys.

Ayouba A, Njouom R, Chia JE, Ahuka-Mundeke S, Kfutwah A, Ngole EM, Nerrienet E, Delaporte E, Peeters M.

Infect Genet Evol. 2015; 30:65-73.

26. La maladie à virus Ebola : pathosystèmes forestiers et risques zoonotiques.

Roger F, Peeters M, Plee L, Bourgarel M.

Bulletin épidémiologique : santé animale/nutrition (BE-ANSES), 2016;(73):20‑2.

27. Development of a sensitive and specific serological assay based on the Luminex technology for the detection of antibodies to Zaire Ebola virus (EBOV).

A.Ayouba, A.Touré, C.Butel, A.Keita, F.Binetruy,  M.Saliou Sow, V.Foulongne, JF.Etard, E.Delaporte, M.Peeters, PostEboGui Study Group.

Journal of Clinical Microbiology 2016;55(1):165-176.

28. Understanding the vulnerability of people with disabilities to HIV and other sexual and reproductive health problems in Cameroon: protocol and methodological considerations

De Beaudrap P, Pasquier E, Noelle  A, et al. HandiVIH.

Open BMJ 2016, 6(2):e008934